Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or AsciminibElias Jabbour, H. Kantarjian, Anna Turkina et al.|JAMA Oncology|2024Cited by 26
A Molecular-Based Ecosystem to Improve Personalized Medicine in Patients with Chronic Myelomonocytic Leukemia (CMML)Luca Lanino, Vladan Vučinić, Yu‐Hung Wang et al.|Blood|2024Cited by 3
Artificial-Intelligence, Data-Driven, Comprehensive Classification of Myeloid Neoplasms Based on Genomic, Morphological and Histological FeaturesLuca Lanino, David Quintela, Yu‐Hung Wang et al.|Blood|2024Cited by 2
Molecular Classification of Chronic Myelomonocytic Leukemia: Results of the Analysis of an International Cohort of 2,471 PatientsLuca Lanino, Rami S. Komrokji, Matteo Zampini et al.|Blood|2023Cited by 1